Floatz logo

Filanesib

Plasma Cell Myeloma

PETHEMA FoundationSmall moleculePhase 2Dormant
BBB
76/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
65/ 100
Competitive Position
95/ 100

Competitive context

475 Active assets in the Plasma Cell Myeloma cohort.

Asset / SponsorPhaseRating
Hyaluronidase fihj
Massachusetts General Hospital
Phase 4BBB
Vincristine sulfate
Roswell Park Cancer Institute
Phase 3BBB
Cyclosporin A
Seoul National University Hospital
Phase 3BBB
ANTI-HUMAN T-LYMPHOCYTE IMMUNOGLOBULIN, RABBIT
University of Birmingham
Phase 4BBB
Epoetin Alfa
Mayo Clinic
Phase 3BB

View all 50 →

Same molecule, other indications

Filanesib is also rated in:

plasma cell leukemiaDormant
CCC
Indicative · Phase 1/2
55 / 100
View asset →
myelodysplastic syndromeDormant
CCC
Indicative · Phase 1/2
52 / 100
View asset →
acute myeloid leukemiaDormant
CC
Indicative · Phase 1/2
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →